3
ALL2
Amgen Inc1
Novartis Pharmaceuticals CorporationYear
3
ALL2
20211
2020DEALS // DEV.
3
ALL3
DevelopmentsCountry
3
ALL1
SWITZERLAND2
U.S.A3
ALL1
Amgen Inc1
Inapplicable1
Novartis Pharmaceuticals CorporationTherapeutic Area
3
ALL3
NeurologyStudy Phase
3
ALL2
Approved FDF1
Phase IVDeal Type
3
ALL3
InapplicableProduct Type
3
ALL3
AntibodyDosage Form
3
ALL3
Subcutaneous InjectionLead Product
3
ALL3
ErenumabTarget
3
ALL3
CGRP receptorLead Product(s) : Erenumab
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results of the study conducted by Novartis showed that patients in the Aimovig treatment arm experienced a significantly lower discontinuation rate due to adverse events and superior efficacy, compared with topiramate.
Product Name : Aimovig
Product Type : Antibody
Upfront Cash : Inapplicable
August 11, 2021
Lead Product(s) : Erenumab
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Erenumab
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aimovig is the First and Only Approved Treatment in Japan to Block the Calcitonin Gene-Related Peptide Receptor (CGRP-R) That Plays an Important Role in Migraine.
Product Name : Aimovig
Product Type : Antibody
Upfront Cash : Inapplicable
June 23, 2021
Lead Product(s) : Erenumab
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The first randomized, double blind, head-to-head study of Aimovig® (erenumab) against topiramate in patients with episodic and chronic migraine (HER-MES) achieved superiority in its primary and secondary endpoints.
Product Name : Aimovig
Product Type : Antibody
Upfront Cash : Inapplicable
February 11, 2020